147 related articles for article (PubMed ID: 35973802)
21. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
22. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Smith RM; Jones RB; Specks U; Bond S; Nodale M; Al-Jayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S; Cheung CK; Derebail V; Doulton T; Ferraro A; Forbess L; Fujimoto S; Furuta S; Gewurz-Singer O; Harper L; Ito-Ihara T; Khalidi N; Klocke R; Koening C; Komagata Y; Langford C; Lanyon P; Luqmani R; McAlear C; Moreland LW; Mynard K; Nachman P; Pagnoux C; Peh CA; Pusey C; Ranganathan D; Rhee RL; Spiera R; Sreih AG; Tesar V; Walters G; Wroe C; Jayne D; Merkel PA;
Ann Rheum Dis; 2023 Jul; 82(7):937-944. PubMed ID: 36958796
[TBL] [Abstract][Full Text] [Related]
23. Association of
Kawasaki A; Sada KE; Kusumawati PA; Hirano F; Kobayashi S; Nagasaka K; Sugihara T; Ono N; Fujimoto T; Kusaoi M; Tamura N; Kusanagi Y; Itoh K; Sumida T; Yamagata K; Hashimoto H; Makino H; Arimura Y; Harigai M; Tsuchiya N
Front Immunol; 2023; 14():1119064. PubMed ID: 36969218
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
25. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
Ozaki S
Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
[TBL] [Abstract][Full Text] [Related]
26. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
[TBL] [Abstract][Full Text] [Related]
27. Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial.
Zonozi R; Cortazar FB; Jeyabalan A; Sauvage G; Nithagon P; Huizenga NR; Rosenthal JM; Sipilief A; Cosgrove K; Laliberte KA; Rhee EP; Pendergraft WF; Niles JL
Ann Rheum Dis; 2024 Feb; 83(3):351-359. PubMed ID: 38123922
[TBL] [Abstract][Full Text] [Related]
28. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse.
Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
Ann Rheum Dis; 2006 Nov; 65(11):1484-9. PubMed ID: 16504995
[TBL] [Abstract][Full Text] [Related]
29. Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment.
Nasrallah M; Pouliot Y; Hartmann B; Dunn P; Thomson E; Wiser J; Butte AJ
Arthritis Res Ther; 2015 Sep; 17(1):262. PubMed ID: 26387933
[TBL] [Abstract][Full Text] [Related]
30. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.
Schirmer JH; Wright MN; Herrmann K; Laudien M; Nölle B; Reinhold-Keller E; Bremer JP; Moosig F; Holle JU
Arthritis Rheumatol; 2016 Dec; 68(12):2953-2963. PubMed ID: 27333332
[TBL] [Abstract][Full Text] [Related]
31. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wu EY; McInnis EA; Boyer-Suavet S; Mendoza CE; Aybar LT; Kennedy KB; Poulton CJ; Henderson CD; Hu Y; Hogan SL; Hu P; Xiao H; Nachman PH; Jennette JC; Falk RJ; Bunch DO
Arthritis Rheumatol; 2019 Nov; 71(11):1894-1903. PubMed ID: 31215772
[TBL] [Abstract][Full Text] [Related]
32. Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis.
Holding S; Fisher VJ; Abuzakouk M
Ann Clin Biochem; 2015 Mar; 52(Pt 2):297-301. PubMed ID: 24723621
[TBL] [Abstract][Full Text] [Related]
33. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.
Miloslavsky EM; Lu N; Unizony S; Choi HK; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Fervenza F; Monach PA; Specks U; Stone JH
Arthritis Rheumatol; 2016 Dec; 68(12):2945-2952. PubMed ID: 27428559
[TBL] [Abstract][Full Text] [Related]
34. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
Kim SM; Choi SY; Kim SY; Kim J
Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
[TBL] [Abstract][Full Text] [Related]
36. Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.
Muto R; Inagaki K; Sato N; Sameshima T; Nagakura Y; Baba S; Kato N; Maruyama S; Akahori T
Intern Med; 2020 Dec; 59(24):3187-3193. PubMed ID: 32788533
[TBL] [Abstract][Full Text] [Related]
37. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series.
Caroti L; Cirami CL; Di Maria L; Larti A; Carta P; Dervishi E; Farsetti S; Tsalouchos A; Novelli L; Minetti EE
BMC Nephrol; 2019 May; 20(1):162. PubMed ID: 31088509
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study.
Culerrier J; Nguyen Y; Karadag O; Yasar Bilge S; Yildrim TD; Ögüt TS; Yazisiz V; Bes C; Celfe A; Yazici A; Sadioglu Cagdas O; Kronbichler A; Jayne D; Gauckler P; Regent A; Teixeira V; Marchand-Adam S; Duffau P; Housz-Oro SI; Droumaguet C; Andre B; Luca L; Lechtman S; Aouba A; Lebas C; Servettaz A; Dernoncourt A; Ruivard M; Milesi AM; Poindron V; Jego P; Padoan R; Delvino P; Vandergheynst F; Pagnoux C; Yacyshyn E; Lamprecht P; Flossmann O; Puéchal X; Terrier B
Rheumatology (Oxford); 2024 Apr; 63(4):999-1006. PubMed ID: 37354498
[TBL] [Abstract][Full Text] [Related]
39. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
40. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
Ann Rheum Dis; 2024 Jan; 83(1):96-102. PubMed ID: 37734880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
